Patient safety is a top priority in cancer drug development. Regulatory agencies like the FDA and EMA have stringent requirements for clinical trials to ensure that new drugs are both safe and effective. Informed consent is essential, where patients are fully educated about the potential risks and benefits of participating in a trial. Post-market surveillance continues to monitor the long-term safety and efficacy of new treatments after they have been approved.
